Trials / Recruiting
RecruitingNCT06727409
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate triple therapy with nsMRA, RASi and SGLT2i on albuminuria in individuals with T2D and CKD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Finerenone | Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy |
Timeline
- Start date
- 2024-12-12
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
- First posted
- 2024-12-10
- Last updated
- 2025-03-05
Locations
1 site across 1 country: Hong Kong
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06727409. Inclusion in this directory is not an endorsement.